Showing results (1-10 of 1,957) with videos related to
Sort By:
Pageof 196
Pharmacotherapy|September 1, 1995
Cost-consequence models for varicella-zoster virus infectionsJ E Paul, J A Mauskopf, L BellPharmacotherapy|March 1, 1997
Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence modelD M Grant, J A Mauskopf, L Bell, et al.Pharmacoeconomics|February 6, 1998
The role of cost-consequence analysis in healthcare decision-makingJ A Mauskopf, J E Paul, D M Grant, et al.Risk Analysis : an Official Publication of the Society for Risk Analysis|December 1, 1987
Projections of cancer risks attributable to future exposure to asbestosJ A MauskopfJAMA|July 10, 1996
Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screeningJ A Mauskopf, J E Paul, D S Wichman, et al.Risk Analysis : an Official Publication of the Society for Risk Analysis|December 1, 1991
Estimating the value of avoiding morbidity and mortality from foodborne illnessesJ A Mauskopf, M T FrenchThe American Journal of Cardiology|December 15, 1991
Cost-effectiveness analysis of the use of digoxin immune Fab (ovine) for treatment of digoxin toxicityJ A Mauskopf, T L WengerAmerican Journal of Public Health|November 1, 1992
A quality-of-life method for estimating the value of avoided morbidityM T French, J A MauskopfClinical Therapeutics|May 24, 2000
Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmineA B Hauber, A Gnanasakthy, J A MauskopfPharmacoeconomics|January 6, 2000
A pharmacoeconomic model for the treatment of influenzaJ A Mauskopf, S C Cates, A D GriffinPageof 196